Postbiotica | From Nature the Future of the Healthcare

POSTBIOTICA is an innovative Biopharmaceutical Company born to develop a new therapeutic treatments based on new molecules with a high biological impact called POSTBIOTICS. We hold a new fermentative process in which we design e modulate the Postbiotics productions.

postbiotica, postbiotics, postbiotics productions, biopharmaceutical company

15847

home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15847,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.7,qode-theme-bridge,wpb-js-composer js-comp-ver-5.5.2,vc_responsive

From Nature the Future of Healthcare

POSTBIOTICA is an innovative Microbiota Biopharmaceutical Company born to develop new therapeutic treatments based on novel molecules with a high biological impact called POSTBIOTICS.
We hold a new fermentative process used to design and modulate POSTBIOTICS production.

SEE THE VIDEO

Science Evidence

Our sound scientific mindset drives Our work. We can demonstrate the effect of POSTBIOTICS through the scientific literature.

Technology

We can design different POSTBIOTICS molecules thanks to Our innovative fermentative process.

Therapeutic Applications

We work everyday to discover new POSTBIOTICS and their therapeutic applications. We have already identified multiple POSTBIOTICS suitable for different therapeutic areas.

Innovation at the 25th IFSCC congress: postbiotics for healthy skin and microbiota.

The 25th edition of the Ifscc conference, an international event dedicated to co...

Postbiotica signs a worldwide licensing agreement with Kalichem to promote postbiotic-based products in the medical device and dermocosmetic area.

Postbiotica has signed a licensing agreement with Kalichem(a Lamberti company) l...

Postbiotica signs a worldwide licensing agreement with Candioli to boost postbiotic-based nutraceuticals in the pet-care area

Postbiotica has signed a licensing and commercialising agreement with Candioli P...

Postbiotics represent an innovative therapeutic approach to prevent NEC

Necrotizing enterocolitis (NEC) primarily affects premature newborns, occurring ...

TEAM

Our team is composed by people with a strongly scientific mindset and specialists, in immune response and in a microbiota field.

Our vision drives our work to improve the technology and discover new possible POSTBIOTIC applications.

JOIN US

Prof. Maria Rescigno

Founder – CEO, CSO

Dott. Giuseppe Penna

Founder – Director, R&D

PhD Francesca Algieri

R&D